NIBIB Biomaterials Network Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) | RFA EB 23 002

Opportunity Information: Apply for RFA EB 23 002

The NIBIB Biomaterials Network Technology Development Coordinating Center funding opportunity (RFA-EB-23-002) is a National Institutes of Health (NIH) discretionary grant program that will support a single, centrally managed Coordinating Center through a U24 cooperative agreement mechanism. It sits within NIHs health research funding portfolio (CFDA 93.286) and is explicitly labeled "Clinical Trial Not Allowed," meaning applicants should not propose work that meets the NIH definition of a clinical trial. The intent, as reflected in the title and mechanism, is to create a hub that coordinates and accelerates technology development activities across a biomaterials network, rather than to run clinical studies.

Because this is a cooperative agreement, the awardee should expect substantial involvement from NIH staff compared with a standard research grant. In practice, that typically means the Coordinating Center would be responsible for organizing network activities, aligning milestones, facilitating communication, and putting shared processes in place to help multiple teams or sites move biomaterials technologies forward efficiently. While the provided text does not spell out specific required cores or tasks, a "technology development coordinating center" commonly functions as an operational backbone for a broader consortium: convening meetings and working groups, maintaining shared resources, supporting collaboration and data/standards practices, tracking progress against network goals, and helping disseminate methods, tools, or best practices to the wider community. The emphasis implied by the FOA is coordination and enablement of technology development in biomaterials, not independent investigator-driven projects or clinical testing.

Eligibility is broad and includes many U.S.-based organization types across government, academia, nonprofit, and industry. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized) and Native American tribal organizations (other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American tribal governments that are not federally recognized, and U.S. territories or possessions.

The opportunity has important restrictions related to foreign involvement. Non-domestic (non-U.S.) entities, including foreign organizations and foreign institutions, are not eligible to apply as the applicant organization. Non-domestic components of U.S. organizations are also not eligible to apply. However, "foreign components" are allowed as defined by the NIH Grants Policy Statement, which generally means a U.S. applicant may include certain elements of work performed outside the U.S. when justified and approved under NIH policy, even though the primary applicant must be domestic.

Administrative details from the notice indicate it was created on March 14, 2023, with an original closing date of May 31, 2023. The award ceiling and expected number of awards are not provided in the supplied source data, so applicants would typically need to consult the full FOA text in NIH systems to confirm budget limits, project period, and whether NIH anticipates one or multiple awards. Overall, the opportunity is best read as NIHs effort to fund an organizing and enabling center that strengthens a biomaterials technology development network through coordination, infrastructure, and shared operational support, while staying outside the scope of clinical trials.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIBIB Biomaterials Network Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286.
• This funding opportunity was created on 2023-03-14.
• Applicants must submit their applications by 2023-05-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA EB 23 002

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: